In vitro and in vivo delivery of novel anticancer fusion protein MULT1E/FasTI via adenoviral vectors

Cancer Gene Therapy

Volumn 17, Issue 3, 2010, Pages 164-170

  Kotturi, H S R ^a,c   Li, J ^b   Branham O'Connor, M ^a   Yu, X ^a,b   Wagner, T E ^a,b   Wei, Y ^a,b  

^a CLEMSON UNIVERSITY   (United States)

^b GREENVILLE HOSPITAL SYSTEM   (United States)

^c UNIVERSITY OF CENTRAL OKLAHOMA   (United States)

Author keywords

Adenoviral gene therapy; Apoptosis; Fas; MULT1; NK cell; NKG2D

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CASPASE 3; HYBRID PROTEIN; PROTEIN FASTI; PROTEIN MULT1E; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD95; APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; MICE; MICE, INBRED C57BL; NEOPLASMS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 76749128820     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.69     Document Type: Article

References (28)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187-376.
2. Diefenbach A, Raulet DH. Strategies for target cell recognition by natural killer cells. Immunol Rev 2001; 181: 170-184.
3. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990; 11: 237-244.
4. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-729.
5. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000; 1: 119-126.
6. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunor-eceptor in immune cell activation and natural killing. Immunity 2002; 17: 19-29.
7. Diefenbach A, Tomasello E, Lucas M, Jamieson AM, Hsia JK, Vivier E et al. Selective associations with signaling molecules determines stimulatory versus costimulatory activity of NKG2D. Nat Immunol 2002; 3: 1142-1149.
8. Malarkannan S, Shih PP, Eden PA, Horng T, Zuberi AR, Christianson G et al. The molecular and functional characterization of a dominant minor H antigen, H60. J Immunol 1998; 161: 3501-3509.
9. Carayannopoulos LN, Naidenko OV, Fremont DH, Yokoyama WM. Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol 2002; 169: 4079-4083.
10. Diefenbach A, Hsia JK, Hsiung MY, Raulet DH. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur J Immunol 2003; 33: 381-391.
11. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10: 26-35.
12. Houston A, O'Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 2004; 4: 321-426.
13. Groh V, Wu J, Yee C, Spies T. Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-738.
14. Sahh HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169: 4098-4102.
15. Moller P, Koretz K, Leithauser F, Bruderlein S, Henne C, Quentmeier A et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal andneo-plastic colon epithelium. Int J Cancer 1994; 57: 371-377.
16. Ivanov VN, Bergami PL, Maulit G, Sato TA, Sassoon D, Ronai Z. FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol 2003; 23: 3623-3635.
17. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396: 699-703.
18. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA et al. BCL-X, a BCL-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
19. Sarid R, Sat T, Bohenzky RA, Russo JJ, Chang Y. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nature Med 1997; 3: 293-298.
20. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nature Med 1996; 2: 1361-1366.
21. Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA 2000; 97: 10872-10877.
22. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA et al. Caspase-8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nature Med 2000; 6: 529-535.
23. Soengas MS, Capodieci P, Polsky D. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409: 207-211.
24. Kotturi HSR, Li J, Branham-O'Connor M, Stickel SL, Yu X, Wagner TE et al. Tumor cells expressing a fusion protein of MULT1 and Fas are rejected in vivo by apoptosis and NK cell activation. Gene Therapy 2008; 15: 1302-1310.
25. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006; 208: 299-318.
26. Mollinedo F, Gajate C. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist Updat 2006; 9: 51-73.
27. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-809.
28. Tanaka M, Suda T, Yatomi T, Nakamura N, Nagata S. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J Immunol 1997; 158: 2303-2309.